Company intelligence / Profile preview
Viridian Therapeutics
Waltham, Massachusetts, United States
- Ownership
- Public · VRDN
- Development stage
- Other
01
Overview
Both lead programs, veligrotug (VRDN-001, IV) and VRDN-003 (subcutaneous), are monoclonal antibodies targeting IGF-1R and are in global phase 3 trials for thyroid eye disease. Both have demonstrated positive topline data, meeting all primary and secondary endpoints in their respective phase 3 studies. FcRn inhibitors (VRDN-006 and VRDN-008) are in earlier clinical stages for autoimmune diseases[4][5].
- Therapeutic areas
- ImmunologyEndocrinology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Viridian Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viridian Therapeutics.